Becton, Dickinson and Company (NYSE:BDX – Get Free Report) has earned a consensus recommendation of “Moderate Buy” from the eight ratings firms that are covering the company, Marketbeat.com reports. One equities research analyst has rated the stock with a hold recommendation and seven have given a buy recommendation to the company. The average twelve-month target price among analysts that have issued ratings on the stock in the last year is $282.38.
Several research firms recently issued reports on BDX. Piper Sandler lowered their price objective on Becton, Dickinson and Company from $305.00 to $280.00 and set an “overweight” rating on the stock in a report on Friday, November 10th. Citigroup lowered their price target on Becton, Dickinson and Company from $282.00 to $260.00 in a research note on Monday, October 2nd. Barclays increased their price objective on Becton, Dickinson and Company from $284.00 to $303.00 and gave the company an “overweight” rating in a research note on Monday, August 7th. Raymond James lowered their target price on shares of Becton, Dickinson and Company from $304.00 to $269.00 and set an “outperform” rating on the stock in a research note on Friday, November 10th. Finally, TheStreet cut shares of Becton, Dickinson and Company from a “b” rating to a “c+” rating in a research report on Thursday, November 9th.
Insider Buying and Selling
Institutional Trading of Becton, Dickinson and Company
Several institutional investors and hedge funds have recently bought and sold shares of the stock. Bank Julius Baer & Co. Ltd Zurich raised its stake in shares of Becton, Dickinson and Company by 98,105.4% in the 2nd quarter. Bank Julius Baer & Co. Ltd Zurich now owns 6,929,375 shares of the medical instruments supplier’s stock valued at $1,829,424,000 after acquiring an additional 6,922,319 shares during the period. Providence Capital Advisors LLC increased its holdings in Becton, Dickinson and Company by 25,185.5% in the 1st quarter. Providence Capital Advisors LLC now owns 4,492,216 shares of the medical instruments supplier’s stock valued at $18,147,000 after purchasing an additional 4,474,450 shares during the last quarter. Moneta Group Investment Advisors LLC boosted its stake in Becton, Dickinson and Company by 95,813.8% in the fourth quarter. Moneta Group Investment Advisors LLC now owns 4,045,643 shares of the medical instruments supplier’s stock valued at $1,028,807,000 after acquiring an additional 4,041,425 shares in the last quarter. Norges Bank purchased a new position in shares of Becton, Dickinson and Company during the fourth quarter worth about $697,398,000. Finally, Osaic Holdings Inc. increased its position in shares of Becton, Dickinson and Company by 1,353.9% during the second quarter. Osaic Holdings Inc. now owns 1,680,292 shares of the medical instruments supplier’s stock worth $31,207,000 after purchasing an additional 1,564,723 shares in the last quarter. 86.72% of the stock is currently owned by hedge funds and other institutional investors.
Becton, Dickinson and Company Trading Up 0.6 %
Shares of BDX stock opened at $235.07 on Friday. Becton, Dickinson and Company has a 1-year low of $218.82 and a 1-year high of $287.32. The company has a market cap of $68.20 billion, a price-to-earnings ratio of 47.39, a PEG ratio of 1.90 and a beta of 0.55. The company has a debt-to-equity ratio of 0.57, a current ratio of 1.31 and a quick ratio of 0.81. The stock has a 50 day simple moving average of $257.13 and a 200-day simple moving average of $260.83.
Becton, Dickinson and Company (NYSE:BDX – Get Free Report) last issued its quarterly earnings results on Thursday, November 9th. The medical instruments supplier reported $3.42 EPS for the quarter, hitting the consensus estimate of $3.42. The company had revenue of $5.09 billion during the quarter, compared to analyst estimates of $5.02 billion. Becton, Dickinson and Company had a net margin of 7.66% and a return on equity of 13.91%. The firm’s revenue was up 6.8% compared to the same quarter last year. During the same quarter in the previous year, the firm earned $2.75 EPS. On average, equities research analysts expect that Becton, Dickinson and Company will post 12.83 EPS for the current fiscal year.
Becton, Dickinson and Company Increases Dividend
The company also recently declared a quarterly dividend, which will be paid on Friday, December 29th. Stockholders of record on Friday, December 8th will be given a dividend of $0.95 per share. This is a boost from Becton, Dickinson and Company’s previous quarterly dividend of $0.91. The ex-dividend date of this dividend is Thursday, December 7th. This represents a $3.80 annualized dividend and a dividend yield of 1.62%. Becton, Dickinson and Company’s payout ratio is presently 76.61%.
About Becton, Dickinson and Company
Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical industry, and the general public worldwide. The company's BD Medical segment provides peripheral intravenous (IV) and advanced peripheral catheters, central lines, acute dialysis catheters, vascular care and preparation products, needle-free IV connectors and extensions sets, closed-system drug transfer devices, hazardous drug detections, hypodermic syringes and needles, anesthesia needles and trays, enteral syringes, and sharps disposal systems; IV medication and infusion therapy delivery systems, medication compounding workflow systems, automated medication dispensing and supply management systems, and medication inventory optimization and tracking systems; syringes, pen needles, and other products for diabetes; and prefillable drug delivery systems.
- Five stocks we like better than Becton, Dickinson and Company
- Manufacturing Stocks Investing
- Amazon, Target, Walmart in a race for fastest delivery
- The How and Why of Investing in Gold Stocks
- Palo Alto Networks: the one security stock to rule them all
- How to Invest in Pharmaceutical Companies
- Is it time to buy the dip in Walmart shares?
Receive News & Ratings for Becton Dickinson and Company Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Becton Dickinson and Company and related companies with MarketBeat.com's FREE daily email newsletter.